Search

Your search keyword '"Reiman, A."' showing total 558 results

Search Constraints

Start Over You searched for: Author "Reiman, A." Remove constraint Author: "Reiman, A." Journal alzheimer's & dementia Remove constraint Journal: alzheimer's & dementia
558 results on '"Reiman, A."'

Search Results

1. Genetic associations with dementia‐related proteinopathy: Application of item response theory

2. Transethnic genome‐wide scan identifies novel Alzheimer's disease loci

4. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

7. Florbetapir PET Measurements of Amyloid Plaque Deposition are More Closely Correlated with Cross‐Sectional and Longitudinal Cognitive and Clinical Measurements Using a White Matter Reference Region of Interest

8. White matter hyperintensities: A long‐term consequence of repetitive head impacts?

9. Informed consent process experience in Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Colombia trial

11. APOE3 Christchurch heterozygosity delays clinical onset in autosomal dominant Alzheimer’s disease

15. Fluid Biomarkers for Neurobehavioral Dysregulation in Former American Football Players

16. Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

18. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

19. Origin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease

20. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease

21. Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease

22. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials

23. APOE and immunity: Research highlights

24. Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial

25. Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease

26. Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer’s Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study

27. Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial

28. APOE ε4 and global cognitive functioning in individuals with autosomal dominant Alzheimer’s disease due to the PSEN1 E280A variant

30. Head‐to‐Head Comparison of Four Plasma Phospho‐Tau Immunoassays in the Neuropathological Diagnosis of Alzheimer’s Disease

32. Plasma neurofilament light chain in cognitively unimpaired late middle‐aged & older adult APOE ε4 homozygotes, heterozygotes, & non‐carriers from the Arizona APOE Cohort

33. Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial

34. APOE3 Christchurch mutation carriers from the Colombian kindred with autosomal dominant Alzheimer’s disease due to PSEN1 E280A

36. Serotonin Reuptake Inhibitors are Associated with Less Amyloid‐β Burden Spatial Extent in Military Veterans with only PTSD, but not with TBI or Comorbid PTSD/TBI: Preliminary PET Findings from ADNI‐DOD Project

38. Effect of APOE4 on Plasma Phospho‐tau 217 and Neurofilament Light in the PSEN1 E280A Autosomal Dominant Alzheimer’s Disease Colombian Kindred

39. Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease

40. Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial

41. Head‐to‐Head Comparison of Four Plasma Phospho‐Tau Immunoassays in the Neuropathological Diagnosis of Alzheimer’s Disease

42. Effect of APOE4 on Plasma Phospho‐tau 217 and Neurofilament Light in the PSEN1 E280A Autosomal Dominant Alzheimer’s Disease Colombian Kindred

43. APOE ε4 and global cognitive functioning in individuals with autosomal dominant Alzheimer’s disease due to the PSEN1 E280A variant

44. APOE3 Christchurch mutation carriers from the Colombian kindred with autosomal dominant Alzheimer’s disease due to PSEN1 E280A

45. Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study

47. Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial

48. Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer’s Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study

49. API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

50. Serotonin Reuptake Inhibitors are Associated with Less Amyloid‐β Burden Spatial Extent in Military Veterans with only PTSD, but not with TBI or Comorbid PTSD/TBI: Preliminary PET Findings from ADNI‐DOD Project

Catalog

Books, media, physical & digital resources